(NP (NP (DT This) (NN paper) (NNS deals)) (PP (IN with) (NP (NP (DT the) (NN estimation)) (PP (IN of) (NP (NP (NNS regions)) (PP (IN of) (NP (NP (NP (NN attraction)) (-LRB- -LRB-) (NP (NNS RoAs)) (-RRB- -RRB-)) (PP (IN under) (NP (NP (JJ parametric) (NNS uncertainties)) (PP (IN for) (NP (DT a) (NML (NN cancer) (NN growth)) (NN model))))))))))) (PP (IN with) (NP (VBN combined) (NNS therapies))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (DT a) (NN framework)) (PP (IN of) (NP (JJ probabilistic) (NN certification)))) (, ,) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ randomized) (NNS methods)))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB derive) (ADVP (RB probabilistically)) (NP (NP (JJ certified) (NNS RoAs)) (PP (IN of) (NP (DT a) (NML (NN cancer) (NN growth)) (NN model))))))))) (. .))
(S (NP (NP (DT The) (NN model)) (SBAR (WHNP (WDT that)) (S (NP (PRP we)) (VP (VBP consider) (PP (IN in) (NP (DT this) (NN paper))))))) (VP (VBZ describes) (NP (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NN tumor)))) (CC and) (NP (NP (JJ immune) (NN system)) (PP (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (DT a) (VBN combined) (NML (NN chemo) (HYPH -) (CC and) (NN immunotherapy))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP model) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (DT the) (NN chemotherapy) (NN agent)))) (PP (IN in) (NP (NP (DT the) (NN body)) (PP (IN via) (NP (DT a) (JJ pharmacokinetic) (NN equation)))))) (. .))
